Free Trial
→ Uranium Mine Flood That Sparked a 2006 Price Surge Returns (From Digest Publishing) (Ad)tc pixel
NASDAQ:IMVT

Immunovant Q3 2025 Earnings Results & Report

Immunovant logo
$37.04 +1.33 (+3.72%)
Closing price 04:00 PM Eastern
Extended Trading
$37.03 -0.01 (-0.03%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant missed analyst earnings expectations in its Q3 2025 results, released February 10, 2025. The company reported EPS of -$0.76 versus the -$0.68 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
6:00 AM ET

Immunovant EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.68
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Immunovant Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Immunovant's Q3 2025 Press ReleasePress Release
(8-K)
Immunovant's Q3 2025 Quarterly reportQuarterly report
(10-Q)

Immunovant Q3 2025 Earnings FAQ

Immunovant (NASDAQ:IMVT) reported earnings of -$0.76 per share for Q3 2025, missing the consensus estimate of -$0.68. The report was announced on Monday, February 10, 2025.

Immunovant Earnings Headlines

Immunovant (IMVT) Q2 2027 Earnings Call Transcript
November 9 at 11:30 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/immunovant-imvt-q2-2027-earnings-020328896.html
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
November 9 at 6:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4965305-immunovant-inc-imvt-q2-2027-earnings-call-transcript
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
November 11 at 1:00 AM  |  Weiss Ratings (Ad)
Immunovant, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026
November 9 at 1:28 PM  |  marketscreener.comM
S&P 500 Futures Up in Premarket Trading; Immunovant, Roivant Sciences Lead
November 9 at 8:27 AM  |  barrons.comhttps://www.barrons.com/articles/s-p-500-futures-up-in-premarket-trading-immunovant-roivant-sciences-lead-7a4d80dc
Immunovant IMVT-1402 RA Win Shapes a $6.3 Billion Bet on the FDA
November 9 at 8:27 AM  |  247wallst.comhttps://247wallst.com/cards/immunovant-q2-2027-earnings-imvt-01m703n5f59bmgkhs2th7749ff
See More Immunovant Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email.

About Immunovant

Immunovant (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies.

The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders. Its medicines are investigational and are not approved for commercial use.

Immunovant was launched by Roivant Sciences in 2018 and remains part of the Roivant group. The company is led by President and Chief Executive Officer Peter Salzmann.

View Immunovant Profile
Earnings Tools